Format

Send to

Choose Destination
Sex Transm Dis. 2014 Feb;41(2):79-85. doi: 10.1097/OLQ.0000000000000088.

Comparing azithromycin and doxycycline for the treatment of rectal chlamydial infection: a retrospective cohort study.

Author information

1
From the Departments of *Epidemiology and †Medicine, University of Washington, Seattle, WA; ‡Public Health-Seattle & King County HIV/STD Program, Seattle, WA; and §Department of Global Health, University of Washington, Seattle, WA.

Abstract

BACKGROUND:

Centers for Disease Control and Prevention guidelines recommend azithromycin or doxycycline for treatment of rectal chlamydial infection.

METHODS:

We created a retrospective cohort of male patients diagnosed as having rectal chlamydia between 1993 and 2012 at a sexually transmitted disease clinic in Seattle, Washington. Men were included in the analysis if they were treated with azithromycin (1 g single dose) or doxycycline (100 mg twice a day × 7 days) within 60 days of chlamydia diagnosis and returned for repeat testing 14 to 180 days after treatment. We compared the risk of persistent/recurrent rectal chlamydial infection among recipients of the 2 drug regimens using 4 follow-up testing time intervals (14-30, 60, 90, and 180 days).

RESULTS:

Of 1835 cases of rectal chlamydia diagnosed in the study period, 1480 (81%) were treated with azithromycin or doxycycline without a second drug active against Chlamydia trachomatis. Of these, 407 (33%) of 1231 azithromycin-treated men and 95 (38%) of 249 doxycycline-treated men were retested 14 to 180 days after treatment (P = 0.12); 88 (22%) and 8 (8%), respectively, had persistent/recurrent infection (P = 0.002). Persistent/recurrent infection was higher among men treated with azithromycin compared with doxycycline at 14 to 30 days (4/53 [8%] vs. 0/20 [0%]), 14 to 60 days (23/136 [17%] vs. 0/36 [0%]), and 14 to 90 days (50/230 [22%] vs. 2/56 [4%]). In multivariate analysis, azithromycin-treated men had a significantly higher risk of persistent/recurrent infection in the 14 to 90 days (adjusted relative risk, 5.2; 95% confidence interval, 1.3-21.0) and 14 to 180 days (adjusted relative risk, 2.4; 95% confidence interval, 1.2-4.8) after treatment.

CONCLUSIONS:

These data suggest that doxycycline may be more effective than azithromycin in the treatment of rectal chlamydial infections.

PMID:
24413484
PMCID:
PMC4364392
DOI:
10.1097/OLQ.0000000000000088
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center